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78 The Journal of Thoracic and Cardiobjective: The prognosis of gastroesophageal junction adenocarcinoma is unques-
ionably related to the extent of nodal involvement; nonetheless, few studies deal
ith the pattern of lymph node spread and specifically analyze the prognostic value
f the site of metastasis. The present study was aimed at evaluating these key aspects
n advanced gastroesophageal junction adenocarcinoma.
ethods: Of 219 patients consecutively operated on for gastroesophageal junction
denocarcinoma at the Department of General Surgery and Surgical Oncology,
niversity of Siena, and at the Department of General Surgery, University of
erona, 143 pT2-4 tumors not submitted to prior chemoradiation were analyzed
ccording to the Japanese Gastric Cancer Association pN staging system.
esults: The majority of patients were given diagnoses of nodal metastases (77.6%).
he mean number (P .076) and the percentage of patients with pN disease (P
022) progressively increased from Siewert type I to type III tumors. Abdominal
odes were involved in all but 1 of the patients with pN disease; conversely, nodal
etastases into the chest were 46.2% for type I, 29.5% for type II, and 9.3% for
ype III tumors. Survival analysis showed virtually no chance of recovery for
atients with more than 6 metastatic nodes or lymph nodes located beyond the
rst tier.
onclusions: In advanced gastroesophageal junction adenocarcinoma, the high
requency of nodal metastases and the related unfavorable long-term outcome
chieved by means of surgical intervention alone are indicative of the need for
ggressive multimodal treatment along with surgical intervention to improve long-
erm results.
denocarcinoma of the gastroesophageal junction (GEJ) remains a neoplasia
of great interest in view of the remarkable increase of incidence observed
during the last decades1,2 and of the unfavorable long-term results achie
y means of surgical intervention alone, even after extended resections.3-5 The
rognosis of GEJ adenocarcinoma is unquestionably related to the extent of nodal
nvolvement,6,7 which is complicated by the regional lymphatic drainage of
umor evenly above and below the diaphragm.8,9
The Japanese literature and some dedicated Western centers extensively inves-
igated the pattern of lymph node spread in stomach cancer to characterize the
attern of dissemination, to define the appropriate extent of nodal dissection, and to
valuate the related prognostic significance.10-12
The mode of diffusion of GEJ adenocarcinoma is less known, and the pattern of
ymph node spread and its prognostic significance have not yet been investigated in
his tumor. The present study was aimed at considering these key aspects in GEJ
denocarcinoma.
vascular Surgery ● August 2007
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TSaterials and Methods
nclusion Criteria and Study Population
EJ adenocarcinoma was defined according to the Siewert classi-
cation.13 The most important inclusion criteria were histolo
iagnosis of adenocarcinoma; no preoperative chemotherapy, ra-
iotherapy, or both; locally advanced tumor (pT2, pT3, and pT4);
acroscopic curative resection (R0-R1); no systemic metastasis;
o history of secondary malignancy; and possibility of follow-up
ith a minimum follow-up period of 18 months. Informed consent
as obtained from all the patients, and the study was approved by
he local ethics committee.
Two hundred nineteen patients affected by GEJ adenocarci-
oma underwent resection at the Department of General Surgery
nd Surgical Oncology, University of Siena, between January
995 and June 2004 and at the Department of General Surgery,
niversity of Verona, between January 1988 and June 2004.
mong these, 76 patients did not match the inclusion criteria and
ere hence excluded from the analysis. In particular, 39 patients
nderwent preoperative chemoradiotherapy (type I, 17 patients;
ype II, 22 patients),14 19 patients underwent macroscopic nonc-
ABLE 1. Main clinicopathologic characteristics accordin
ariable Type I (n  20)
ge (y)
Median (range) 68 (27–90)
ex
Male (n  117) 19 (95)
Female (n  26) 1 (5)
auren type
Intestinal (n  102) 16 (80)
Nonintestinal (n  41) 4 (20)
epth of invasion (pT)
pT2 (n  62) 9 (45)
pT3 (n  69) 11 (55)
pT4 (n  12)† —
odal involvement (pN)
pN0 (n  32) 7 (35)
pN (n  111) 13 (65)
o. of positive nodes
0 (n  32) 7 (35)
1-6 (n  53) 9 (45)
6 (n  58) 4 (20)
ean ( SD) no. of positive nodes 4.2 (7.4)
category
R0 (n  129) 19 (95)
R1 (n  14)‡ 1 (5)
D, Standard deviation. *Numbers in parentheses are percentages. †R0 res
Abbreviations and Acronyms
GEJ  gastroesophageal junction
JGCA Japanese Gastric Cancer Associationesidual disease was at the proximal resection margin in 9 patients, at the dist
The Journal of Thoracicative (R2) surgical intervention (type II, 10 patients; type III, 9
atients), and a pT1 tumor was diagnosed in 18 patients (type I, 7
atients; type II, 8 patients; type III, 3 patients).
Clinical, histopathologic, and follow-up data of the 143 patients
nder study were prospectively collected and presented in Tab
he median age of the cohort was 68 years (range, 27-90 years),
ith a male/female ratio of 4.5 to 1.
taging Work-up
reoperative work-up included a barium swallow, esophagogas-
roscopy with biopsy, and computed tomography of the chest and
bdomen in every case. Endoscopic ultrasonography was per-
ormed in 79 patients, whereas neither thoracoscopy nor laparos-
opy was used in this series of patients for evaluation of tumor
esectability or staging.
urgical Intervention
urgical resection and mode of reconstruction have been previ-
usly described in detail.3 Briefly, the standard procedure for ty
tumors was a right thoracotomy with a subtotal esophagectomy
bove the azygos vein with proximal gastric resection. The pro-
edure of choice for type III tumors was a total gastrectomy with
ranshiatal resection of the distal esophagus. A transthoracic ap-
roach was necessary in 2 cases. Type II tumors were treated with
ubtotal esophagectomy, as in type I cancers, or with total gas-
rectomy with transhiatal or transthoracic resection of the distal
Siewert classification for the 143 patients under study*
Siewert type
P valueType II (n  62) Type III (n  61)
.937
67 (27–90) 68 (36–82)
.137
47 (75.8) 51 (83.6)
15 (24.2) 10 (16.4)
.117
48 (77.4) 38 (62.3)
14 (22.6) 23 (37.7)
.007
32 (51.6) 21 (34.4)
29 (46.8) 29 (47.5)
1 (1.6) 11 (18)
.022
18 (29) 7 (11.5)
44 (71) 54 (88.5)
.036
18 (29) 7 (11.5)
21 (33.9) 23 (37.7)
23 (37.1) 31 (50.8)
7.5 (10.3) 10.4 (13.1) .076
.474
57 (91.9) 53 (86.9)
5 (8.1) 8 (13.1)
was achieved in 10 (83.3%) of 12 patients with pT4 disease. ‡Microscopicg to
ection
al resection margin in 1 patient, and in peritoneal washing in 4 patients.
and Cardiovascular Surgery ● Volume 134, Number 2 379
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TSsophagus, as in type III tumors; the type of resection was chosen
o obtain clear proximal and distal margins and adequate lymph-
denectomy. After subtotal esophagectomy, reconstruction was
erformed with a gastric tube, whereas a jejunal Roux-en-Y re-
onstruction was performed after total gastrectomy.
Lymph node dissection was classified according to the Japa-
ese Gastric Cancer Association (JGCA) rules: D1 lymphadenec-
omy (resection of perigastric nodes in positions 1-4s), D2 lymph-
denectomy (resection of nodes in positions 1-11), and D3
ymphadenectomy (resection extended to the nodes in positions
2-16).15 The preferred lymph node dissection was a stand
ediastinal (including paraesophageal, tracheal bifurcation, right
ronchial, posterior mediastinal, and diaphragmatic nodes) and D2
bdominal lymphadenectomy for type I tumors and D2-D3 abdom-
nal lymphadenectomy added to nodes of the lower posterior
ediastinum for type II and III tumors. Lymphadenectomy at the
plenic hilum was limited to patients with enlarged nodes or
umors reaching the gastric fundus, and it was achieved by means
f pancreas-preserving splenectomy. D1 dissection was reserved
or high-risk patients.
athologic Staging and Assignment to JGCA
odal Station
onsidering the depth of tumor invasion (pT), American Joint
ommittee on Cancer and International Union Against Cancer
ules for esophageal cancer were adopted in Siewert type I tumors,
hereas those for gastric cancer were used in Siewert type II and
II tumors.16 Regarding nodal staging (pN), both the number 
ite of nodal metastasis were evaluated in each case. The number-
ased classification was derived from the American Joint Com-
ittee on Cancer and International Union Against Cancer classi-
cation for gastric cancer,16 and 3 classes were considered: 
ositive nodes, 1 to 6 positive nodes, and greater than 6 positive
odes. The site-based classification adhered to the criteria stated by
he JGCA.15 Perivisceral lymph nodes were dissected from 
xcised specimen by the surgeon immediately after resection,
ssigned to the appropriate station according to the JGCA classi-
cation, and sent for histologic examination. The second- and
hird-tier nodes were subdivided by the surgeon himself during
ymphadenectomy, as described in a previous study,17 to avoid
rrors caused by difficulties in assigning nodes to the correct
ymph node station after en bloc resection.
According to the JGCA, stations 1, 2, 3, and 4s were regarded
s first-tier nodes; inversely, other lymph nodes were termed
on–first tier. Additionally, paraesophageal nodes of the lower
hird (station 110) were considered as first-tier nodes in type I
umors.
The histologic classification followed the criteria of Lauren,
nd mixed-type tumors were considered together with the diffuse
ype (nonintestinal type).
ollow-up
fter discharge from the hospital, all patients were followed up
fter 4 months and subsequently at 6-month intervals until their
eath or the time of study (December 2005). None of the patients
as lost to follow-up. The median follow-up period for surviving
atients was 46.5 months (range, 18.2-208.1 months). t
80 The Journal of Thoracic and Cardiovascular Surgery ● Augutatistical Analysis
he 2 test was used for categoric data and the analysis of va
est for continuous variables was used to evaluate the significance
f differences among Siewert types.
Survival curves were estimated by using the Kaplan–Meier
ethod and compared by using the log–rank test. Multivariate
nalysis was performed with the Cox regression model to evaluate
he independent prognostic value of lymph node involvement.
elative risks in relation to the site and number of nodal metas-
ases were considered separately and derived by controlling for
ge, sex, Siewert type, Lauren type, pT, and R category. Deaths
rom causes other than GEJ adenocarcinoma were considered
ensored observations at the time of death. Patients who died
uring the postoperative period were computed in survival analy-
is. Analyses were performed with the Statistical Product and
ervice Solutions (SPSS 12.0 for Windows XP; SPSS, Inc, Chi-
ago, Ill).
esults
n the series of 143 patients, a total of 5357 lymph nodes
as retrieved and analyzed, with a mean number  SD per
atient of 37.5 20.3. The mean SD number of dissected
odes was 23.4  10.8 for type I, 37.3  19.9 for type II,
nd 42.3  21.1 for type III tumors (P  .001). A mean 
D of 18.8  10.1 nodes was removed by means of D1
ymphadenectomy, 35.2  17.1 by means of D2 lymphad-
nectomy, and 47.8  20.5 by means of D3 lymphadenec-
omy (P  .001).
ncidence of Nodal Metastases
etastases were diagnosed in 1186 lymph nodes in 111
77.6%) patients for a mean SD of 8.3 11.4. The mean
D number (P  .076) and the percentage of patients with
N disease (P  .022) progressively increased from type
 to type III tumors (Table 1). The incidence of 
etastases, as well as the mean number of involved nodes
P  .042), significantly correlated with the depth of tumor
nvasion (pT). Lesions with invasion limited to the visceral
all (pT2) had a 61.3% incidence of pN disease; it was
8.4% for pT3 tumors, whereas all pT4 lesions showed
odal metastases (P  .001). More than 6 metastatic nodes
ere present in 18 (29.0%) patients with pT2 disease, in 31
44.9%) patients with pT3 disease, and in 9 (75%) patients
ith pT4 disease (P  .001).
istribution of Nodal Metastases
he conformity and pertinence of lymphadenectomy eval-
ated according to the total/mean number of retrieved nodes
or each JGCA station and to the percentage of patients in
hich each single JGCA station had been retrieved are
eported in Table 2. Figure 1 correlates the distributio
odal metastases with the location of the tumor according to
iewert classification.
The site and level of nodal metastases for the 3 Siewert
ypes in the 111 node-positive patients is reported in
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G
TSable 3. All but 1 of the patients with pN disease
howed an involvement of abdominal nodes (99.1%);
onversely, nodal metastases into the chest were diag-
osed in 6 (46.2%) type I, 13 (29.5%) type II, and 5
9.3%) type III tumors.
urvival Analysis
able 4 reports survivals according to the main clinicop
logic characteristics of the cohort under study. It is note-
orthy that virtually no chance of recovery was observed
or patients with more than 6 metastatic nodes (P  .001).
Survival according to the presence of nodal metastasis is
eported for each JGCA nodal station in Table 5. Rem
bly, among patients with pN disease, long-term survival
as restricted to a small proportion of patients with involve-
ent limited to the first-tier perigastric nodes. One patient
ith deposits in a single lymph node located at the left
astric artery (station 7) survived beyond 60 months.
Multivariate analysis confirmed the independent prog-
ostic value of nodal involvement, both considering the
umber (relative risk with respect to pN0, 2.20 [95% CI,
.10–4.39 with 1–6 nodes] and 5.00 [95% CI, 2.47–10.12
ith 6 nodes]; P  .001) and site (relative risk with
espect to pN0, 1.86 [95% CI, 0.90–3.84 with first-tier
odes] and 4.13 [95% CI, 2.11–8.12 with non–first-tier
ABLE 2. Conformity and pertinence of lymphadenectomy
tudy*
Lymph node station (JGCA)
1 Right paracardial
2 Left paracardial
3 Lesser curvature 1
4s Greater curvature
4d Right gastroepiploic artery
5 Suprapyloric
6 Infrapyloric
7 Left gastric artery
8 Common hepatic artery
9 Celiac trunk
10 Splenic hilum
11 Splenic artery
12 Hepatoduodenal ligament
16 Para-aortic
07 Subcarinal
08 Paraesophageal middle third
10 Paraesophageal lower third
11 Supradiaphragmatic
12 Posterior mediastinal
GCA, Japanese Gastric Cancer Association. *Numbers in parentheses rep
ssociation station has been retrieved.odes]; P  .001) of nodal metastases. r
The Journal of Thoracic-
iscussion
he major findings of the present study are as follows: (1)
odal involvement is confirmed as a common event in
dvanced GEJ adenocarcinoma; (2) the pattern of lymph
ode spread herein observed was somewhat different among
he 3 Siewert types; (3) abdominal nodes were involved in
lmost all patients with pN disease; and (4) long-term
urvival was mostly limited to patients with pN0 disease
nd to patients with fewer than 7 metastatic nodes located
ithin the first tier.
Reported data about the nodal spread of GEJ adenocar-
inoma are scanty and hard to compare because of a lack of
n overall consensus on the definition, staging, and treat-
ent of this tumor.9,13,18,19
Surgical treatment is considered the mainstay of therapy,
nd its founding oncologic principle is focused on the com-
leteness of tumor removal (R0 resection), which has proved
o be essential for achieving long-term survival.3,20,21 Progno-
is of GEJ adenocarcinoma is poor because advanced depth
f invasion of the visceral wall and lymph node involve-
ent are usually present at onset3,18,22; accordingly, mor
han three fourths of our patients were diagnosed with n
eposits. As is well established, lymph node involvement
roved to be a significant predictor of survival6,7,23 and a
ajor determinant of locoregional recurrence.24,25 For these
rding to Siewert classification for the 143 patients under
Total/mean no. of retrieved nodes
pe I Type II Type III
6 (95) 257/4.4 (95.2) 190/3.7 (85.2)
2 (95) 158/2.7 (93.5) 83/1.8 (77)
1 (100) 413/6.8 (98.4) 533/8.7 (100)
8 (60) 101/1.9 (83.9) 155/3.4 (75.4)
1 (10) 123/2.9 (67.7) 168/3.7 (75.4)
44/1.1 (67.7) 26/0.6 (72.1)
148/3.7 (64.5) 168/3.6 (77)
2 (75) 160/3.0 (87.1) 136/2.8 (80.3)
1 (55) 180/4.0 (72.1) 144/4.2 (55.7)
4 (60) 117/2.9 (64.5) 129/3.7 (57.4)
2 (5) 37/1.8 (33.9) 78/2.8 (45.9)
9 (55) 72/2.0 (58.1) 69/2.3 (49.2)
2 (20) 66/2.8 (38.7) 93/3.9 (39.3)
140/5.4 (41.9) 174/6.4 (44.3)
3 (70) 38/2.1 (29) 8/4 (3.3)
5 (75) 22/1.7 (21) 4/2 (3.3)
3 (85) 65/1.9 (54.8) 40/2.1 (31.1)
6 (70) 40/1.6 (40.3) 40/1.8 (35.5)
1 (80) 62/2.2 (45.1) 46/2.1 (35.5)
t the percentage of patients in which each single Japanese Gastric Canceracco
Ty
49/2.
37/
01/5.
10/0.
2/
—
—
30/
23/2.
29/2.
21/1.
8/
—
32/2.
22/1.
39/2.
22/1.
34/2.
reseneasons, lymphadenectomy is considered key in the surgical
and Cardiovascular Surgery ● Volume 134, Number 2 381
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TSreatment of this tumor. Nonetheless, great controversy con-
inues over the optimal extent of lymph node dissection in
he absence of prospective randomized trials demonstrating
clear benefit of extended versus limited lymphadenecto-
Figure 1. Percentage of nodal involvement to each J
station according to the tumor location (Siewert type
ABLE 3. Location of nodal metastases according to Siew-
rt classification for the 111 patients with pN disease*
Siewert type
Type I
(n  13)
Type II
(n  44)
Type III
(n  54)
evel of nodal metastasis
First tier (n  43) 6 (46.2) 15 (34.1) 22 (40.7)
Non–first tier (n  68) 7 (53.8) 29 (65.9) 32 (59.3)
ite of nodal metastasis
Abdomen (n  87) 7 (53.8) 31 (70.5) 49 (90.7)
Abdomen and chest
(n  23)
6 (46.2) 13 (29.5) 4 (7.4)
Chest (n  1) — — 1 (1.9)lNumbers in parentheses are percentages.
82 The Journal of Thoracic and Cardiovascular Surgery ● Auguies.26-28 In addition, understanding the mode in wh
EJ adenocarcinoma spreads to lymph nodes and the re-
ated prognostic significance is helpful in defining the ap-
ropriate extent of nodal dissection and in tailoring the most
ppropriate treatment for this tumor.
As already seen in radioisotope lymphography29 and
eported in clinical studies,8,9,30,31 lymphatic pathways ar
ainly directed toward the abdomen. In fact, abdominal
iers were involved in virtually all patients with pN dis-
ase, and metastases confined to abdominal nodes were
0.7%, 70.5%, and 53.8% in type III, type II, and type I
umors, respectively. Conversely, the overall rate of nodal
etastases into the chest were 46.2% for type I, 29.5% for
ype II, and 9.3% for type III tumors, and isolated metasta-
es to mediastinal nodes were rarely observed (1 patient).
In Siewert type I tumors paraesophageal nodes of the
ower third (station 110) were infiltrated in 1 of 4 patients,
hereas metastases were less frequently diagnosed in type
I (12.9%) and type III (3.3%) tumors. Dresner and col-
ese Gastric Cancer Association (JGCA) lymph node
e II, and type III) for the 143 patients under study.apaneagues8 reported double that rate of paraesophageal node
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TSnvolvement in 104 cases of type I cancers and a percentage
f about 5% in 48 cases of type II tumors. On the other
and, the incidence of metastases to supradiaphragmatic
station 111) and lower mediastinal nodes are comparable
station 112), with data reported by Dresner and colleag8
nd Yuasa and associates.32 As reported in Table 2, on
bout one third of patients with Siewert type III tumors had
ediastinal lymph nodes retrieved. This is due to the fact
hat two thirds of tumors reached the GEJ with a marginal
nvasion of the esophagus, and hence the involvement of
ediastinal stations was considered unusual. Certainly, this
tatement cannot be regarded as definitive without a com-
lete clearing of chest nodes in each case.
Subcarinal node (station 107) involvement was identified
n 5% of type I and 1.6% of type II tumors. Nigro and
oworkers9 reported slightly higher percentages in 8 (13
ABLE 4. Survival according to main clinicopathologic
haracteristics for the 143 patients under study
ymph node station
JGCA)
No. of patients
(no. alive)
Median
survival*
5-y
survival†
P
value‡
ge .200
Median 71 (25) 21.4 27.7
Median 72 (18) 19.0 22.2
ex .643
Male 117 (34) 19.0 22.6
Female 26 (9) 19.3 33.5
iewert type .401
Type I 20 (5) 15.5 18.7
Type II 62 (22) 23.5 27.1
Type III 61 (16) 17.4 24.5
auren type .001
Intestinal 102 (36) 23.5 30.4
Nonintestinal 41 (7) 12.9 10.4
epth of invasion
(pT)
.001
pT2 62 (26) 36.3 35.2
pT3 69 (15) 16.9 18.4
pT4 12 (2) 7.4 0
o. of positive nodes .001
0 32 (20) — 53.9
1-6 53 (15) 20.0 25.9
6 50 (8) 12.7 3.9
evel of positive
nodes
.001
pN0 32 (20) — 53.9
First tier 43 (13) 19.5 28.7
Non–first tier 68 (10) 14.7 5.5
category .001
R0 129 (43) 22.3 27.8
R1 14 (0) 6.9 0
GCA, Japanese Gastric Cancer Association. *For pN0, median survival was
eyond the observation period. †Five-year survival was calculated by using
he Kaplan–Meier method. ‡P value was computed by using the log–rank test.ases of distal esophageal and in 36 (8.3%) cases of GEJ m
The Journal of Thoracicdenocarcinoma in patients who underwent en bloc esoph-
gectomy for tumors with transmural growth. Dresner and
olleagues,8 in the above-mentioned study, recorded a p-
entage of about 10% in type I and 0% in type II cancers.
Taking into account abdominal lymphatic spread, lesser
urvature (station 3) and right paracardial nodes (station 1)
ere the most frequently involved. Less common was the
nvolvement of stations along the left side of the stomach
stations 2, 4, and 6).
Altogether, the 3 Siewert types often spread to second-tier
bdominal nodes. Above all, left gastric artery nodes (station 7)
ere affected in 20% of type I (14%–60%), 30.6% of type II
18%– 65%), and 18% in type III (10%– 42%) tumors.8,9,31-33
ikewise, the percentage of metastases to the common hepatic
rtery (station 8) and celiac trunk nodes (station 9) cannot be
onsidered negligible (10%–17.7%).
Interestingly enough, para-aortic node metastases (sta-
ion 16) were an extremely common event when consider-
ng type III cancers. Nodal diffusion to para-aortic stations
as present in 13.1% of all resected patients and in the
9.6% of patients who underwent D3 lymphadenectomy
data not shown). Consistently, a rate of 30% was reported
y Hsu and associates.34
Considering the data reported here, it should be taken into
ccount that in this clinical study, the extent of lymph node
issection was tailored according to tumor location, and lymph
ode dissection differed in the 3 Siewert types. As a conse-
uence, an underestimation of the real frequency of involve-
ent of some nodal stations is possible. As a fact, the above-
entioned data prove the regular involvement of second-tier
and third-tier) nodes in GEJ adenocarcinoma and support the
se of extended lymphadenectomy to achieve complete re-
oval of the tumor. Transthoracic subtotal esophagectomy
ith standard 2-field lymphadenectomy is regarded as the
reatment of choice for type I and type II tumors with signif-
cant esophageal involvement,35 even though some author
aking into account the possibility of metastases to upper
ediastinal36 and cervical19,37 nodes, advocate the use of mo
xtensive lymph node dissection (extended 2-field and 3-field
ymphadenectomy). In view of the high rate of second-tier
bdominal node involvement, the use of D2 lymphadenectomy
eems to be advisable in type I and II tumors, whereas a lymph
ode dissection extended to para-aortic nodes (D3 lymphade-
ectomy) would be justified in type III and type II tumors with
ajor gastric involvement.34,38
Conversely, one could argue that the poor long-term
esults reported in the present, as in previous experiences
fter adequate lymph node clearing,9,18,30,39 do not justify
he use of an extended lymphadenectomy.40 As a matter o
act, in our study little chance of survival was observed for
atients with involvement of second-tier (and third-tier)
ymph nodes,5,18,30 as well as for patients with more tha
etastatic nodes, which confirms the findings reported by
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s staging tools useful in guiding the choice of treatme43
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